Sulfated, low-molecular-weight lignins are potent inhibitors of plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies

Summary

Recently we prepared sulfated, low-molecular-weight lignins (LMWLs) to mimic the biological activities of heparin and heparan sulfate. Chemo-enzymatically prepared sulfated LMWLs represent a library of diverse non-sugar, aromatic molecules with structures radically different from the heparins, and have been found to potently inhibit thrombin and factor Xa. To assess their effect on the fibrinolytic system, we studied the interaction of LMWLs with human plasmin. Enzyme inhibition studies indicate that the three sulfated LMWLs studied inhibit plasmin with IC50 values in the range of 0.24 and 1.3 μM, which are marginally affected in the presence of antithrombin. Similarly, plasmin degradation of polymeric fibrin is also inhibited by sulfated LMWLs. Michaelis-Menten kinetic studies indicate that maximal velocity of hydrolysis of chromogenic substrates decreases nearly 70% in the presence of LMWLs, while the effect on Michaelis constant is dependent on the nature of the substrate. Competitive binding studies indicate that the sulfated LMWLs compete with full-length heparin. Comparison with thrombin-heparin crystal structure identifies an anionic region on plasmin as a plausible sulfated LMWL binding site. Overall, the chemoenzymatic origin coupled with coagulation and fibrinolysis inhibition properties of sulfated LMWLs present novel opportunities for designing new pharmaceutical agents that regulate complex pathologies in which both systems are known to play important roles such as disseminated intravascular coagulation.

Keywords

Plasmin - lignins - heparin mimetics - enzyme inhibition - allostery - anticoagulant - anti-fibrinolytic agent

• References

• 1 Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des 2008; 72: 455-482.
• 2 Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41: 391-412.
• 3 Coombe DR, Kett WC. Heparan sulfate-protein interactions: therapeutic potential through structure-function insights. Cell Mol Life Sci 2005; 62: 410-424.
• 4 Esko JD, Selleck SB. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002; 71: 435-471.
• 5 Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002; 19: 312-331.
• 6 Monien BH, Henry BL, Raghuraman A. et al. Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg Med Chem 2006; 14: 7988-7998.
• 7 Henry BL, Thakkar JN, Martin EJ. et al. Characterization of the plasma and blood anticoagulation potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coag Fibrinol 2009; 20: 27-34.
• 8 Henry BL, Monien BH, Bock PE. et al. A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J Biol Chem 2007; 282: 31891-31899.
• 9 Vörös G, Kolev K, Csomor K. et al. Inhibition of plasmin activity by sulfated polyvinylalcohol-acrylate copolymers. Thromb Res 2000; 100: 353-361.
• 10 Kanai S, Okamoto H, Tamaura Y. et al. Fibrin suspension as a substrate fop plasmin: determination and kinetics. Thromb. Haemost 1979; 42: 1153-1158.
• 11 Lutz H-P, Luisi PL. Correction for inner filter effects in fluorescence spectroscopy. Helv Chim Acta 1983; 66: 1929-1935.
• 12 Parker CA, Barnes WJ. Some experiments with spectro-fluorimeters and filter fluorimeters. Analyst 1957; 82: 606-618.
• 13 Wang X, Lin X, Loy JA. et al. Crystal structure of the catalytic domain of human plasmin complexed with streptokinase. Science 1998; 281: 1662-1665.
• 14 Carter WJ, Cama E, Huntington JA. Crystal structure of thrombin bound to heparin. J Biol Chem 2005; 280: 2745-2749.
• 15 Richardson JL, Kroger B, Hoeffken W. et al. Crystal structure of the human α-thrombin – haemadin complex: an exosite II binding inhibitor. EMBO J 2000; 19: 5650-5660.
• 16 Olson ST, Swanson R, Raub-Segall E. et al. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost 2004; 92: 929-939.
• 17 Jordan RE, Oosta GM, Gardner WT. et al. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255: 10081-10090.
• 18 Machovich R, Bauer PI, Arányi P. et al. Kinetic analysis of the heparin-enhanced plasmin--antithrombin III reaction. Apparent catalytic role of heparin. Biochem J 1981; 199: 521-526.
• 19 Henry BL, Connell J, Liang A. et al. Interaction of antithrombin with sulfated, low molecular weight lignins: Opportunities for potent, selective modulation of antithrombin function. J Biol Chem 2009; 284: 20897-20908.
• 20 Jordan RE, Oosta GM, Gardner WT. et al. The binding of low molecular weight heparin to hemostatic enzymes. J Biol Chem 1980; 255: 10073-10080.
• 21 Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27: 657-666.
• 22 Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35: 2191-2195.
• 23 Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-333.
• 24 Tarui T, Majumdar M, Miles LA. et al. Plasmin-induced migration of endothelial cells: a potential target for the anti-angiogenic action of angiostatin. J Biol Chem 2002; 277: 33564-33570.
• 25 Snyder KM, Kessler CM. The pivotal role of thrombin in cancer biology and tumorigenesis. Semin Thromb Hemost 2008; 34: 734-741.
• 26 Verghese J, Liang A, Sidhu PP. et al. First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa. Bioorg Med Chem Lett 2009; 19: 4026-4029.